Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Denosumab superior to alendronate for BMD loss prevention in malignant lymphoma
01 Jul 2026
bởiStephen Padilla
The use of denosumab demonstrates superior protection against bone mineral density (BMD) loss at 12 months compared with alendronate in older patients with newly diagnosed lymphoma receiving R-CHOP* and related regimens, as shown in the DENOSULY study.








